Cancer Drug Shortage Sparks Rationing Fears

A critical shortage of generic chemotherapy infusions is impacting cancer treatment across the United States, raising concerns about rationing. Doctors are contending with low supplies and unfilled orders for drugs essential to treating numerous cancers.

These decades-old medications, vital for treating cancers like breast, lung, and head and neck cancers, are difficult to produce and command low prices. Manufacturing issues, shipping delays, and companies discontinuing production, as reported by the FDA, have led to the scarcity.

In some hard-hit areas, physicians are making difficult decisions to prioritize scarce doses for patients with the highest likelihood of a full recovery. This often favors younger patients, creating distressing situations for medical professionals, patients, and their families.

Hospitals are experiencing significant shortfalls in orders for crucial drugs like ifosfamide and cisplatin. Some medical practices are implementing conservation measures, such as spacing out doses, to ensure no medication is wasted.

Previous shortages of similar drugs in recent years prompted discussions about durable solutions, but few systemic changes have been implemented. Efforts are underway by federal agencies to alleviate the shortages, including considering temporary imports from international companies. However, international regulators have already warned that supplies might not rebound until next year.

Manufacturing facility issues, including sterility problems, have also contributed to the shortages, impacting the availability of drugs like ifosfamide. While some initiatives are supporting domestic manufacturing of certain chemotherapy drugs, ongoing systemic policy changes are needed to prevent future crises.